New KRAS Inhibitor Elisrasib Shows Strong Results in Advanced Lung Cancer

Non-small cell lung cancer driven by KRAS G12C mutations is one of the most common and difficult-to-treat cancer subtypes. First-generation KRAS inhibitors like sotorasib and adagrasib opened a new treatment era, but resistance remains a major clinical challenge. Elisrasib, an investigational next-generation inhibitor, aims to address that gap.

Presented at the American Association for Cancer Research annual meeting, phase I/II data showed elisrasib achieved an overall response rate of nearly 60% in patients naive to KRAS G12C therapy. At the recommended 600 mg daily dose, median progression-free survival reached 12.2 months and the 12-month overall survival rate was 72%. Median duration of response was an impressive 16.5 months.

Perhaps most clinically significant, approximately one-third of patients whose disease had progressed on prior KRAS G12C inhibitors still responded to elisrasib. This suggests the drug can partially overcome acquired resistance mechanisms that defeat older agents, offering a potential second-line option in a population with few alternatives.

Experts at the meeting praised the data but urged context. Discussant Adrian Sacher noted that elisrasib enters a crowded field where combination strategies pairing KRAS inhibitors with immunotherapy are already advancing rapidly, particularly in frontline metastatic settings. Monotherapy activity, while meaningful, may not be sufficient to define a dominant role for the drug.

For longevity-conscious readers, advances in targeted cancer therapy matter because cancer remains a leading cause of premature death and lost healthspan. Improved KRAS-targeted treatments could meaningfully extend survival for a large patient population. However, this is early-phase data from a relatively small trial, and regulatory approval and broader clinical validation are still required before elisrasib becomes a standard option.